Odin Pharmaceuticals

What Odin Pharmaceuticals does

Odin Pharmaceuticals is a private, US-based sterile pharmaceutical company founded in 2018 by Dr. Veerappan Subramanian and Dr. Ilango Subramanian and headquartered at 300 Franklin Square Drive in Somerset, New Jersey. The company develops, manufactures, and markets generic injectable and ophthalmic drugs for the US healthcare market, with a stated focus on high-barrier-to-entry, difficult-to-develop and difficult-to-manufacture products. Its product portfolio spans five core sterile dosage forms — wet vials, lyophilized vials, pre-filled syringes, ophthalmic droppers, and intravenous bags — produced using aseptic processing and terminal sterilization across six advanced formulation platforms including colloids, emulsions, microsuspensions, nanosuspensions, microspheres, in situ gelling systems, and liposomes and lipid complexes.

The company operates a B2B sales-led distribution model reaching hospitals, clinics, ophthalmologists, optometrists, physicians, veterinarians, retail pharmacies, wholesalers, distributors, group purchasing organizations (GPOs), and government agencies. Pricing is not publicly disclosed and is negotiated through contracts with institutional buyers and GPOs. As of the 2021 groundbreaking, the company is undertaking a $110 million, 110,000-square-foot facility expansion to add multiple manufacturing lines and an expanded R&D center, signaling an intent to scale onshore US sterile manufacturing capacity.

The leadership team is anchored by founders with a documented track record of building and exiting three prior pharmaceutical companies (Kali Laboratories sold to Par Pharma in 2005; Novel Laboratories and GAVIS Pharmaceuticals sold to Lupin in 2015) collectively valued at $1.1 billion. The current executive bench draws senior operators from Teva, Actavis, Merck, Schering-Plough, Baxter Healthcare, Bausch & Lomb, Ranbaxy, Wockhardt, Alembic, Zydus, and Glenmark. The company has secured regulatory standing with no FDA warning letters under its current management and in 2021 added a respiratory product franchise under a newly hired VP, expanding beyond sterile injectables and ophthalmics into metered dose inhalers, nasal sprays, dry powder inhalers, and nebulizers.

Name

Odin Pharmaceuticals

Legal name

Odin Pharmaceuticals LLC

Website

https://odinpharmaceuticals.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Odin Pharmaceuticals is a private, US-based sterile pharmaceutical company founded in 2018 that develops and manufactures generic injectable and ophthalmic drugs for hospitals, retail pharmacies, wholesalers, group purchasing organizations, and government agencies.

Ownership category

akta.pro rank

Product category

Generic Sterile Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

akta.pro secondary industries

Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Generic injectables
• Sterile pharmaceuticals
• Ophthalmic generics
• Aseptic manufacturing
• Lyophilized injectables

Headquarters

HQ city

Somerset

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Sales: Revenue generated from manufacturing and marketing generic injectable and ophthalmic drugs to the US healthcare market including hospitals, clinics, retail pharmacies, wholesalers, and government agencies
2. Product Commercialization: Direct commercialization of ANDA-based generic pharmaceutical products across multiple dosage forms including sterile injectables and ophthalmics through established distribution channels

Go-to-market motion2 records

Distribution channels5 records

Core offering

Odin Pharmaceuticals is a sterile pharmaceutical company that develops, manufactures, and markets generic injectable and ophthalmic drugs for the US healthcare market. The company focuses on difficult-to-develop and difficult-to-manufacture high-barrier-to-entry products, producing multiple sterile dosage forms including wet vials, lyophilized vials, pre-filled syringes, ophthalmic droppers, and intravenous bags using aseptic processing and terminal sterilization.

Product overview

Odin Pharmaceuticals is a sterile pharmaceutical company that manufactures and markets generic injectable and ophthalmic drugs for the US healthcare market. The company's product portfolio spans five core sterile dosage forms: Wet Vials, Lyophilized Vials, Pre-filled Syringes, Ophthalmic Droppers, and Intravenous Bags. These products are developed using six advanced pharmaceutical technology platforms including Colloids and Emulsions, Microsuspensions and Nanosuspensions, Microspheres, Insoluble Salts and Drug Complexes, In Situ Gelling Systems, and Liposomes and Lipid Complexes. The company focuses on difficult-to-develop and difficult-to-manufacture products utilizing aseptic processing and terminal sterilization.

Differentiator

Problem solved

Functional benefit

Products and services

• Wet Vials Sterile liquid injectable dosage form packaged in vials, produced using aseptic processing or terminal sterilization for ophthalmic and general injectable applications in hospital, clinic, and pharmacy settings.
• Lyophilized Vials Freeze-dried injectable dosage form packaged in vials, produced using lyophilization processing technology and requiring reconstitution prior to administration, for hospital and clinical use.
• Pre-filled Syringes Sterile injectable dosage form pre-packaged in syringes, offering ready-to-administer convenience for healthcare providers in hospitals, clinics, and other care settings.
• Ophthalmic Droppers Sterile ophthalmic dosage form packaged in dropper bottles for topical ocular administration, prescribed by ophthalmologists, optometrists, and other physicians.
• Intravenous Bags Sterile liquid injectable dosage form packaged in IV bags for intravenous infusion administration in hospital and clinical care settings.

Quantifiable outcome

• Over 300 successful commercial drug product launches generating $800 million in revenues
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Hikma Pharmaceuticals: Major US generic sterile injectables manufacturer with comparable product portfolio including vials, pre-filled syringes, and ophthalmics; sells through the same GPO/wholesaler channels.
• Amphastar Pharmaceuticals: US-based specialty generic injectables and inhalation company; most directly comparable given similar focus on difficult-to-make sterile generics and complex dosage forms including respiratory.
• Fresenius Kabi: Global generic sterile injectables player with strong US presence in IV bags, vials, and pre-filled syringes; competes head-to-head in hospital channels.
• Somerset Therapeutics: Smaller US sterile injectable and ophthalmic generics manufacturer with similar product mix; Odin's CFO previously served as CFO here, indicating close operational overlap.

Broad incumbents

• Sandoz (Novartis): Global generic injectables leader; broad portfolio across sterile and ophthalmic dosage forms overlapping substantially with Odin's planned products.
• Lupin Pharmaceuticals: Acquired Novel Laboratories and GAVIS Pharmaceuticals (founders' prior companies) in 2015; directly comparable therapeutic and dosage-form focus with established US sterile injectable footprint.
• Hospira (Pfizer CenterOne): Largest US generic sterile injectables franchise (acquired by Pfizer); sets pricing benchmarks and dominates hospital contracts that Odin must win against.

Emerging players

• Aurobindo Pharma USA: Growing US sterile injectables and ophthalmic generics presence; competes on price in shared dosage forms but with broader global scale.
• Bausch + Lomb: Specialized ophthalmic pharmaceutical manufacturer with significant US generic and branded ophthalmic portfolio; competes directly in Odin's ophthalmic dropper category.
• Slayback Pharma: US-based specialty generics company with overlap in sterile injectables and complex dosage forms; Odin's VP of Quality previously served here, indicating talent and operational overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/odin-pharmaceuticals-llc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Odin Pharmaceuticals